PGP-0729

PGP-0729 is a preclinical-stage therapeutic candidate being developed by ProGenis Pharmaceuticals for the primary indication of muscle preservation. The program is designed to address conditions characterized by muscle loss or wasting, such as sarcopenia or cachexia. As of early 2026, the asset remains in the preclinical phase of development. Detailed information regarding its specific molecular target, mechanism of action, and modality (e.g., small molecule or biologic) has not been publicly disclosed by the sponsor, though it is a key component of ProGenis's pipeline focused on muscle health and regenerative medicine.